Patent intelligence · US
US 11446357
Method for treating disease using FOXP3+CD4+ T cells
Method for treating disease using FOXP3+CD4+ T cells
Patent details — US 11446357
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 20, 2022
- Expiration
- Sep 15, 2042
- Applicant
- Kyverna Therapeutics, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K38/1709, A61K38/177, A61K38/1774
Quick answer
US 11446357 (Method for treating disease using FOXP3+CD4+ T cells) is held by Kyverna Therapeutics, Inc.. Status: granted. Granted Sep 20, 2022. Expires Sep 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kyverna Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K38/1709, A61K38/177, A61K38/1774, A61K38/1793, A61K39/3955
More from Kyverna Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11446357?
US 11446357 (Method for treating disease using FOXP3+CD4+ T cells) is held by Kyverna Therapeutics, Inc.. Status: granted. Granted Sep 20, 2022. Expires Sep 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11446357?
Kyverna Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 11446357 expire?
Our index shows an expiration date of Sep 15, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.